Hansa Biopharma AB (publ) (HNSA.ST)
SEK 33.3
(17.42%)
SEK 33.3
(17.42%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 866.76 Million SEK | 9.57% |
| 2022 | 791.09 Million SEK | 2136.05% |
| 2021 | 35.37 Million SEK | 601.27% |
| 2020 | 5.04 Million SEK | -46.66% |
| 2019 | 9.45 Million SEK | 1539.34% |
| 2018 | 577 Thousand SEK | 43.18% |
| 2017 | 403 Thousand SEK | 739.58% |
| 2016 | 48 Thousand SEK | -47.25% |
| 2015 | 91 Thousand SEK | -30.0% |
| 2014 | 130 Thousand SEK | -74.94% |
| 2013 | 518.72 Thousand SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | -100.0% |
| 2009 | 8 Million SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 947.12 Million SEK | 9.27% |
| 2024 Q2 | 974.48 Million SEK | 2.89% |
| 2024 Q3 | 942.95 Million SEK | -1.57% |
| 2023 FY | 866.76 Million SEK | 9.57% |
| 2023 Q4 | 866.76 Million SEK | -6.78% |
| 2023 Q2 | 865.84 Million SEK | 5.03% |
| 2023 Q1 | 824.4 Million SEK | 4.21% |
| 2023 Q3 | 929.81 Million SEK | 7.39% |
| 2022 FY | 791.09 Million SEK | 2136.05% |
| 2022 Q3 | 791.01 Million SEK | 2376.34% |
| 2022 Q1 | 33.67 Million SEK | -4.81% |
| 2022 Q2 | 31.94 Million SEK | -5.15% |
| 2022 Q4 | 791.09 Million SEK | 0.01% |
| 2021 Q1 | 3.85 Million SEK | -23.65% |
| 2021 FY | 35.37 Million SEK | 601.27% |
| 2021 Q3 | 20.16 Million SEK | -6.26% |
| 2021 Q4 | 35.37 Million SEK | 75.41% |
| 2021 Q2 | 21.51 Million SEK | 458.54% |
| 2020 Q4 | 5.04 Million SEK | -18.98% |
| 2020 Q3 | 6.22 Million SEK | -15.85% |
| 2020 FY | 5.04 Million SEK | -46.66% |
| 2020 Q1 | 8.56 Million SEK | -9.47% |
| 2020 Q2 | 7.4 Million SEK | -13.58% |
| 2019 Q2 | 33.77 Million SEK | 121.83% |
| 2019 Q4 | 9.45 Million SEK | -76.17% |
| 2019 Q3 | 39.69 Million SEK | 17.52% |
| 2019 Q1 | 15.22 Million SEK | 2538.82% |
| 2019 FY | 9.45 Million SEK | 1539.34% |
| 2018 Q1 | 652 Thousand SEK | 61.79% |
| 2018 Q2 | 668 Thousand SEK | 2.45% |
| 2018 Q4 | 577 Thousand SEK | -50.98% |
| 2018 Q3 | 1.17 Million SEK | 76.2% |
| 2018 FY | 577 Thousand SEK | 43.18% |
| 2017 Q4 | 403 Thousand SEK | -31.93% |
| 2017 Q1 | 597 Thousand SEK | 1143.75% |
| 2017 Q3 | 592 Thousand SEK | -0.34% |
| 2017 Q2 | 594 Thousand SEK | -0.5% |
| 2017 FY | 403 Thousand SEK | 739.58% |
| 2016 Q3 | 591 Thousand SEK | 1274.42% |
| 2016 Q4 | 48 Thousand SEK | -91.88% |
| 2016 Q2 | 43 Thousand SEK | 2.38% |
| 2016 FY | 48 Thousand SEK | -47.25% |
| 2016 Q1 | 42 Thousand SEK | -53.85% |
| 2015 Q4 | 91 Thousand SEK | 121.95% |
| 2015 Q3 | 41 Thousand SEK | 0.0% |
| 2015 Q2 | 41 Thousand SEK | -99.2% |
| 2015 Q1 | 5.12 Million SEK | 3839.23% |
| 2015 FY | 91 Thousand SEK | -30.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q4 | 130 Thousand SEK | 0.0% |
| 2014 FY | 130 Thousand SEK | -74.94% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | 518.72 Thousand SEK | 0.0% |
| 2013 Q4 | 518.72 Thousand SEK | -20.2% |
| 2013 Q3 | 650 Thousand SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 FY | - SEK | -100.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2009 Q4 | 8 Million SEK | 0.0% |
| 2009 FY | 8 Million SEK | 0.0% |
| 2008 Q4 | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -5284.656% |
| Ziccum AB (publ) | 857 Thousand SEK | -101039.79% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -17308.476% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -3439.562% |
| Genovis AB (publ.) | 79.32 Million SEK | -992.748% |
| Intervacc AB (publ) | 181 Thousand SEK | -478777.348% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -4105.366% |
| Active Biotech AB (publ) | 3 Million SEK | -28792.267% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | -1337.379% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -17235.36% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | -1113.808% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -10972.662% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -204326.415% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | -698.129% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -28133.485% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -33495.659% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -86576.8% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 11.476% |
| Camurus AB (publ) | 24.5 Million SEK | -3436.818% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -3044.337% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Cyxone AB (publ) | 858 Thousand SEK | -100921.911% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -50558.562% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | -2254.836% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -130045.345% |
| SynAct Pharma AB | 637 Thousand SEK | -135970.33% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -101872.706% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -49120.216% |
| BioInvent International AB (publ) | 23.24 Million SEK | -3628.997% |
| Alzinova AB (publ) | 800 Thousand SEK | -108246.0% |
| Oncopeptides AB (publ) | 106.48 Million SEK | -713.966% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -112018.798% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | -855.222% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -2725.926% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | -274.448% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -81593.497% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |